Last reviewed · How we verify
ALXN1720
At a glance
| Generic name | ALXN1720 |
|---|---|
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis (PHASE3)
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis (PHASE3)
- PK Study of Gefurulimab SC in Healthy Chinese Adult Participants (PHASE1)
- A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants (PHASE1)
- Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria (PHASE1)
- Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALXN1720 CI brief — competitive landscape report
- ALXN1720 updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI